1. Retinopathy

Internal Medicine

Volumn 36, Issue 2, 1997, Pages 136-138

  Hotta, Nigishi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aldose reductase inhibitor; Anticoagulant drugs; Electroretinogram; Polyol pathway

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ANTICOAGULANT AGENT; BERAPROST; FIDARESTAT; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC RETINOPATHY; ELECTRORETINOGRAM; NERVE CONDUCTION; NONHUMAN; RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DISEASE PROGRESSION; ELECTRORETINOGRAPHY; HUMANS;

EID: 0030887953     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.36.136     Document Type: Article

References (18)

1. Davis MD. Diabetic retinopathy - A clinical overview. Diabetes Care 15: 1844, 1992.
2. Kohner EM. Diabetic retinopathy. Br Med J 307: 1195, 1993.
3. Klein R, Davis MD, Mose SE, Klein BEK, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: A comparison of retinopathy in younger and older onset diabetic persons. In: Comparison of Type I and Type II Diabetes. Vranic M, Hollenberg C, Steiner G, Eds. New York, Plenum, 1985, p. 321.
4. Dvornik D. Aldose Reductase Inhibition - An Approach to the Prevention of Diabetic Complications. McGraw-Hill, New York, 1987.
5. Hotta N, Sakamoto N. Aldose reductase inhibitors. In: The Diabetes Annual 5. Alberti KGMM, Krall LP, Eds. Excerpta Medica, Amsterdam, 1990, p. 330.
6. Hotta N. New approaches for treatment in diabetes: aldose reductase inhibitors. Biomed Pharmacother 49: 232, 1995.
7. Akagi Y, Kador PF, Kuwabara T, Kinoshita JH. Aldose reductase localization in human retinal mural cells. Invest Ophthalmol Vis Sci 24: 1516, 1983.
8. Hotta N, Kakuta H, Ando F, et al. Diabetic retinopathy - Experimental and clinical approaches from polyol pathway. In: Current Concepts of Aldose Reductase and Its Inhibitions. Sakamoto N, Kinoshita JH, Kador PF, Hotta N, Eds. Elsevier Science Publishers BV, Amsterdam, 1990, p. 169.
9. Kador PF, Akagi Y, Takahashi Y, Ikebe M, Wyman M, Kinoshita JH. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 108: 1301, 1990.
10. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315, 1988.
11. Yonemura D, Aoki T, Tsuzuki K. Electroretinogram in diabetic retinopathy. Arch Ophthalmol 68: 49, 1962.
12. Simonsen SE. ERG in diabetes. In: The Clinical Value of Electroretinography. Francois J, Ed. Karger Basel. New York, 1968, p. 403.
13. Sato S, Sugimoto S, Ando T, Miyajima H, Chiba S. An electrophysiological method for detecting diabetic retinopathy in rats. Folia Pharmacol Jpn 84: 509, 1984.
14. Hotta N, Koh N, Sakakibara F, et al. An aldose reductase inhibitor, TAT, prevents electroretinographic abnormalities and ADP-induced hyperaggregability in streptozotocin-induced diabetic rats. Eur J Clin Invest 25: 948, 1995.
15. Hotta N, Koh N, Sakakibara F, et al. Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats. Exp Physiol 80: 981, 1995.
16. Hotta N, Koh N, Sakakibara F, et al. Effects of beraprost sodium and insulin on the electroretinogram, nerve conduction, and nerve blood flow in rats with streptozotocin-induced diabetes. Diabetes 45: 361, 1996.
17. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977, 1993.
18. Gordon B, Chang S, Kavanagh M, et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 112: 385, 1991.